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BioadhesionAbstract Delivery of orally compromised therapeutic drug molecules to the systemic circulation
via buccal route has gained a signiﬁcant interest in recent past. Bioadhesive polymers play a major
role in designing such buccal dosage forms, as they help in adhesion of designed delivery system to
mucosal membrane and also prolong release of drug from delivery system. In the present study,
HPMC (release retarding polymer) and mannitol (diluent and pore former) were used to prepare
bioadhesive and controlled release buccal discs of buspirone hydrochloride (BS) by direct compres-
sion method. Compatibility of BS with various excipients used during the study was assessed using
DSC and FTIR techniques. Effect of mannitol and HPMC on drug release and bioadhesive
strength was studied using a 32 factorial design. The drug release rate from delivery system
decreased with increasing levels of HPMC in formulations. However, bioadhesive strength of for-
mulations increased with increasing proportion of HPMC in buccal discs. Increased levels of man-
nitol resulted in faster rate of drug release and rapid in vitro uptake of water due to the formation of
channels in the matrix. Pharmacokinetic studies of designed bioadhesive buccal discs in rabbits
316 A. Jaipal et al.demonstrated a 10-fold increase in bioavailability in comparison with oral bioavailability of buspi-
rone reported.
ª 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Buccal route along with other transmucosal routes (such as
nasal, pulmonary, rectal) has long been advocated as possible
route of drug administration for systemic delivery of drugs
with poor and/or erratic bioavailability. Buccal route has
many advantages over other transmucosal route such as ease
of application and removal (Harris and Robinson, 1992).
Moreover, buccal route helps in avoidance of ﬁrst pass metab-
olism, erratic oral absorption of drug due to food interactions
and at the same time limits the exposure of drugs to harsh gas-
tric environment. The relative immobility of buccal mucosa as
compared to that of other transmucosal routes makes this site
ideal for sustained delivery of drugs. Thus, adhesive dosage
forms such as tablets (Choi and Kim, 2000), discs (Jaipal
et al., 2013; Yehia et al., 2008), gels (Morishita et al., 2001),
sprays (Pozzilli et al., 2005), solutions (Muchohi et al., 2008),
patches or ﬁlms (Giovino et al., 2012; Kianfar et al., 2013)
have been reported for buccal delivery of drugs. Solid unit dos-
age forms (such as discs and tablets) are most preferred for
buccal delivery as they supply the dose accurately when com-
pared to other dosage forms listed above (Abruzzo et al.,
2012). Moreover, buccal discs are ﬂat, thin solid unit non-ﬂex-
ible compacts; and are similar to buccal tablets. Buccal discs
are designed to minimize the discomfort caused due to bulky
tablet buccal dosage forms (Jaipal et al., 2014). Solid dosage
forms are easier to prepare and the process can easily be scaled
up for large scale manufacturing.
Polymers with bioadhesive and drug release retarding prop-
erties have widely been reported in literature for effective deliv-
ery of orally compromised drugs via buccal route. These
polymers help the delivery system adhere to buccal mucosa
and at the same time retard the release of drug (Abruzzo
et al., 2012; Andrews et al., 2009; Boyapally et al., 2010;
Kianfar et al., 2013; Martin et al., 2003; Rossi et al., 2005;
Salamat-Miller et al., 2005).
Hydroxy propyl methyl cellulose (HPMC) is a semi syn-
thetic and inert bioadhesive polymer. HPMC is GRAS (gener-
ally recognized as safe) listed ingredient and included in FDA’s
Inactive Ingredient database used in manufacturing of variety
of dosage forms available commercially. HPMC is available in
a wide range of viscosity grades (3–100,000 mPa) (Nafee et al.,
2004). Biocompatible and biodegradable nature of HPMC
along with bioadhesive and release rate retarding properties
of HPMC make it a suitable excipient for designing buccal
discs (Mumtaz and Ch’ng, 1995; Narendra et al., 2005;
Taylan et al., 1996).
Mannitol is a white crystalline polyol synthesized industri-
ally by catalytic hydrogenation of fructose or glucose syrup.
Mannitol is water soluble, non toxic and non hygroscopic ingre-
dient extensively used in food and pharmaceutical preparations
(Debord et al., 1987). Mannitol is GRAS (generally recognized
as safe) listed ingredient and is used in many dosage forms
available commercially. It has been reported that mannitolenhances dissolution of drug from the dosage form as it forms
pores within the dosage form matrix (Holgado et al., 1995).
Buspirone hydrochloride (BS), is an anxiolytic agent and a
serotonin receptor partial agonist belonging to the azaspirod-
ecanediones class of compounds (Blier and Ward, 2003;
Sramek et al., 2002). BS does not possess anticonvulsant or
muscle relaxant properties and also does not cause sedation
or physical dependence like other anxiolytics (Riblet et al.,
1983; Taylor et al., 1985). After oral administration, BS is rap-
idly and erratically absorbed in humans and undergoes exten-
sive ﬁrst pass metabolism resulting is very low oral
bioavailability of approximately 4% (Mahmood and
Sahajwalla, 1999). Following oral administration, plasma con-
centrations of unchanged BS are very low and with a very high
inter and intra subject variability (Lilja et al., 1998; Ratey
et al., 1989; Realmuto et al., 1989). Peak plasma concentration
of BS varies in the presence of food (Lilja et al., 1998;
Mahmood and Sahajwalla, 1999). These pharmacokinetic
properties make BS a suitable candidate for delivery via buccal
route.
The objective of the present investigation was to develop
and evaluate buccal bioadhesive discs of BS for improvement
of bioavailability. Buccal disc were formulated using HPMC
as bioadhesive and rate controlling polymer and mannitol as
a pore former. Effect of polymer amount and amount of man-
nitol on drug release behavior, drug release rate and bioadhe-
sive properties of designed buccal discs was assessed. This
effect of HPMC and mannitol was studied statistically using
32 full factorial design. Bioadhesive buccal discs of BS using
xanthan gum (Jaipal et al., 2013) and HPMC with effervescent
agents (Jaipal et al., 2014) were previously reported by our
group. In the present research effect of HPMC and mannitol
on drug release and bioadhesion behavior is reported. To the
extent of our knowledge, the effect of HPMC and mannitol
on drug release and bioadhesive behavior have not been
reported for the drug BS using factorial design method. More-
over, in vivo pharmacokinetic parameters for the designed
buccal discs are also reported in comparison with i.v bolus.
2. Materials and methods
Buspirone hydrochloride (BS) was provided as a gift sample by
Astron Research Limited, India. Hydroxy propyl methyl cellu-
lose (HPMC 15K) was provided as gift sample by Signet
Chemical Corporation, India. Mannitol was purchased from
Sigma–Aldrich Corporation. Cellulose microcrystalline (Avi-
cel PH101) was purchased from FMC BioPolymer, India.
HPLC grade acetonitrile was purchased from Merck, India
and deionized water used for in vitro and analytical studies
were obtained using a Millipore water puriﬁcation system
(Milli-Q). Nylon membrane ﬁlters of pore diameter 0.22 lm
were purchased from Millipore India. Other reagents and
chemicals used were of analytical grade. Solid phase extraction
cartridges (HyperSep Retain PEP 30 mg, 1 mL capacity) were
purchased from Thermo Scientiﬁc India Limited, India.
Table 2 Factors selected for 32 full factorial design along with
levels and amounts of respective factors.
Factors Levels (mg)
1 0 +1
X1: HPMC K15 15.00 18.75 22.50
X2: mannitol 22.50 30.00 37.50
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In-vitro sample analysis was performed using validated liquid
chromatographic method. The liquid chromatographic system
employed was Shimadzu HPLC (Shimadzu, Japan) with sol-
vent delivery system of two pumps (Model LC 10AT VP), auto
injector (Model SIL HT A) and UV–VIS detector (Model SPD
10A VP). Data collection and integration was accomplished
using LC Solutions software. Column oven (Model CTO-
10AS) was used to maintain column temperature at 25 C.
Chromatographic separation was performed using a C8
column (LiChroCART; 250 mm · 4.6 mm ID, 5 lm) main-
tained at 25 C using mobile phase ﬂow rate of 1 mL/min.
Drug was monitored at 238 nm with an injection volume of
50 lL. Analysis was performed in triplicate for all the samples.
The mobile phase constituted of acetonitrile and 0.025 M
potassium phosphate buffer pH 3.0 (25:75 v/v). The buffer
pH was adjusted with orthophosphoric acid (0.1 M). The buf-
fer solution was passed through 0.22 lm ﬁlters prior to use.
Liquid chromatographic method used for estimation of BS
in rabbit plasma employed same chromatographic conditions
as discussed above. Sumatriptan was used as an internal stan-
dard (IS) while estimating the drug content in in vivo samples.
BS and IS in rabbit plasma were detected at 9.19 and 13.00 min
of retention time respectively with tailing factor less than
1.36 ± 0.03.
2.2. Drug excipient compatibility studies
Compatibility of BS with various excipients was assessed using
Differential Scanning Calorimetry (DSC, Shimadzu, Japan)
and Fourier Transform Infra Red (FTIR) Spectroscopy (Shi-
madzu-Prestige 21, Japan). DSC thermograms and FTIR spec-
tra of pure drug, pure excipients and 1:1 mixture of drug and
excipient were compared to assess compatibility. For DSC
study, sample (2–4 mg) was weighed accurately in aluminum
pans and thermogram was acquired over a temperature range
of 30–300 C with a heating rate of 10 C per minute in a nitro-
gen gas environment. FTIR spectroscopic studies were carried
out by appropriately diluting the sample with dried potassium
bromide and acquiring infra red (IR) spectrum in the range of
400–4000 cm1 with 2 cm1 resolution.
2.3. Preparation of buccal discs
Buccal discs containing 10 mg of BS were prepared by direct
compression method. All the ingredients were passed throughTable 1 Composition, drug content, thickness, friability and surfac
B. noa HPMC 15 K (mg) Mannitol (mg) MCC (mg) Drug
F1 15.00 22.50 26.00 100.4
F2 15.00 30.00 18.50 98.0
F3 15.00 37.50 11.00 100.1
F4 18.75 22.50 22.25 98.8
F5 18.75 30.00 14.75 100.0
F6 18.75 37.50 7.25 99.6
F7 22.50 22.50 18.50 101.2
F8 22.50 30.00 11.00 98.8
F9 22.50 37.50 3.50 101.8
a All the batches contain 10 mg BS and 1.50 mg of magnesium stearatesieve (#18) and mixed geometrically; ﬁnally magnesium stea-
rate (2%) was added as lubricant (Table 1). The resulting
mix was compressed using a 10 station compression machine
(Rimek Mini Press, India) equipped with 5 mm punches. Com-
position of all the designed buccal discs is presented in Table 1.
Weight of the designed discs was kept constant for all the
batches by adjusting ﬁnal weight with cellulose microcrystal-
line, a directly compressible diluent having negligible effect
on drug release and bioadhesive behavior over wide range of
concentrations (Badhan et al., 2009).
A 32 full factorial design was employed to study the effect
of varying amount of HPMC and mannitol on drug release
and bioadhesive behavior of buccal discs of BS. Amount of
HPMC was varied at three levels viz. 15.00 mg, 18.75 mg
and 22.50 mg. Similarly amount of mannitol was varied at
three levels viz. 22.50 mg, 30.00 mg and 37.50 mg (Table 2).
The amount of HPMC 15 K (Factor: X1) and mannitol (Fac-
tor: X2) was selected as independent variable and the depen-
dent response variables measured were percent drug release
at 5 h (Q5 in percent), time required to release 50% of drug
(T50 in h) and bioadhesive strength (FN in Newton). The
effect of formulation variables on the response variables was
studied and statistically analyzed by applying one-way
ANOVA at 0.05 level using Design-Expert version 8.0.7.1
(Stat-Ease Inc.). The data obtained were ﬁtted into quadratic
model and were supported by 3D surface response plots to
illustrate the effect of HPMC and Mannitol on dependent vari-
ables. Experiments were conducted in random sequence with
levels of factors coded. In all the designed batches, discs weight
(75 mg) was kept constant by adding appropriate amount of
microcrystalline cellulose.
To describe the response surface curvature, the design was
evaluated by quadratic model given by polynomial equation
(Eq. (1)).
Y ¼ B0 þ B1X1 þ B2X2 þ B11X21 þ B22X22 þ B12X1X2 ð1Þ
where ‘Y’ is the dependent variable, B0 is arithmetic mean
response of 9 batches and B1 is the estimated coefﬁcient ofe pH of the designed buccal discs.
content (%) Thickness (mm) Friability (%) Surface pH
0 2.511 ± 0.010 0.27 6.86 ± 0.15
6 2.496 ± 0.006 0.53 6.91 ± 0.20
4 2.501 ± 0.017 0.13 7.01 ± 0.15
0 2.395 ± 0.021 0.60 6.86 ± 0.10
6 2.467 ± 0.015 0.33 7.03 ± 0.11
7 2.505 ± 0.010 0.73 6.59 ± 0.24
3 2.506 ± 0.011 0.27 7.16 ± 0.23
0 2.516 ± 0.006 0.27 6.94 ± 0.16
1 2.488 ± 0.020 0.40 7.02 ± 0.23
.
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average effect of one factor at a time from low to high value
(Narendra et al., 2005). The interaction terms (X1X2) show
how response changes when 2 factors are changed
simultaneously. The polynomial equations can be used to draw
conclusions after considering the magnitude of coefﬁcient and
the mathematical sign it carries (i.e., positive or negative).
2.4. Physical characterization of buccal discs
2.4.1. Weight variation
From each batch randomly selected buccal discs (20) were
evaluated for weight variation using an electronic digital
weighing balance (Mettler Toledo TA 250D). Mean weight
of the buccal discs and percentage deviation was calculated.
2.4.2. Thickness
Thickness of buccal discs (10) was measured in millimeter
using Vernier Caliper (Mitutoyo Digimatic Caliper, Japan).
The mean thickness of buccal discs and percent standard
deviation was calculated.
2.4.3. Friability
Friability analysis of the designed discs was assessed using fri-
ability test apparatus (Campbell Electronics, India) for 20 discs
using standard procedure (25 rpm for 4 min). The percentage
loss on friability (F) was calculated.
2.4.4. Surface pH
Acidic or alkaline pH of the dosage form could cause uneasi-
ness in the oral cavity and may lead to irritation. Surface pH
for all the batches was determined in triplicate using a digital
pH meter (Eutech Instruments, Singapore). The buccal discs
were hydrated in 100 mL distilled water for 20 min. The elec-
trode upon contact with the hydrated buccal discs surface
was allowed to equilibrate for 1 min and the pH was recorded
immediately. All the readings were recorded in triplicates.
2.4.5. Drug content
Randomly selected buccal discs (10) were crushed using mortar
and pestle. Powder equivalent to 2 mg of BS was weighed
accurately and BS was extracted using 10 mL of solvent system
(acetonitrile and Phosphate buffer pH 3.0; 1:3 v/v). The resul-
tant mix was centrifuged at 3000 rpm (Remi-R8C laboratory
centrifuge) and 1 mL of supernatant was collected and suitably
diluted for the determination of drug content by liquid chro-
matographic method mentioned in the previous section.
2.4.6. In-vitro water uptake studies
Water uptake studies of the designed buccal discs were
performed on 2% aqueous agar plates maintained at 37 C
and 40% RH in a humidity chamber. The percent water
uptake was calculated at different time points. All the readings
were recorded in triplicate for each time point. Percent water
uptake was calculated for all the batches using Eq. (1).
Percent water uptake ¼ Final weight Initial weightð Þ
Initial weight
 100
ð1Þ2.4.7. In-vitro bioadhesion studies
Bioadhesion studies of designed formulations were carried out
using texture analyzer (Stable Micro Systems TA-XT Plus).
Freshly excised porcine buccal mucosa was obtained from
the local slaughterhouse. The tissue was placed in simulated
salivary ﬂuid and stored at 20 C till further usage. The
thawed mucosal membrane was ﬁxed at the base of instrument
using a Teﬂon hollow disc and screws in temperature con-
trolled bath containing simulated salivary ﬂuid with pH 6.75
as described elsewhere (Gohel et al., 2009). Designed buccal
disc was attached to the base of the texture analyzer movable
probe (SMSP/10) using a double sided adhesive tape. The
probe was lowered at a speed of 0.5 mm/s. Upon contact of
buccal disc with mucosal membrane a contact force of
0.01 N was applied for 300 s. The probe was then dragged in
opposite direction and force required to detach the buccal disc
from the mucosal surface was recorded.
2.4.8. In-vitro drug release studies
Previously reported in-house modiﬁed USP type-1 dissolution
apparatus (Charde et al., 2008) was used to study the drug
release rate from designed buccal bioadhesive discs. Brieﬂy,
the method uses 50 mL capacity screw cap tubes arranged con-
centric to the shaft of dissolution apparatus using in-house
designed aluminum holder. Single unit of buccal disc was
loaded in the basket attached to the instrument shaft and
allowed to immerse in the prearranged tubes containing
50 mL pH 6.8 phosphate buffer maintained at 37 C. The
instrument was operated at 25 rpm and samples were collected
at various time intervals of 0.5, 1, 2, 3, 4 and 5 h. The samples
collected were analyzed for drug content using liquid chro-
matographic method described previously. All the drug release
studies were performed in triplicates.
2.4.9. Drug release kinetics
Drug release rate from hydrophilic matrix systems depends on
swelling behavior of the polymer, shape of the matrices, and
diffusion and erosion properties of the polymer and dissolu-
tion characteristics of the drug. Dose and solubility of the
drug, type and quantity of the ﬁllers and the polymer charac-
teristics inﬂuence the mechanism of the drug release (Baveja
et al., 1988; Korsmeyer et al., 1983a, b). Data obtained from
the drug release studies were ﬁtted into zero order, ﬁrst order,
Higuchi and Korsmeyer–Peppas models to predict the drug
release kinetics and mechanism from the designed HPMC buc-
cal discs (Gurny et al., 1982; Korsmeyer et al., 1983b; Peppas
and Sahlin, 1996).
2.4.10. In-vivo pharmacokinetic study
The efﬁciency of HPMC buccal discs to deliver BS into
systemic blood circulation was evaluated in rabbits. Male
New Zealand white rabbits were provided by Central Animal
Facility of the Institute with mean weight of 1.65 ± 0.15 kg.
The study was conducted with an approval (Protocol approval
number: IAEC/RES/16/04) and as per guidelines prescribed by
Institutional Animal Ethics Committee, and under the supervi-
sion of registered veterinarian. Animals were issued 10 days
prior to experimentation for acclimatization and were kept
on standard pellet diet and water ab libitum. Animals were
fasted 4–6 h prior to experimentation.
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To the ﬁrst group 1 mL of BS solution in sterile water (10 mg/
mL) was administered intravenously. The second group was
administered designed HPMC buccal bioadhesive controlled
release discs of BS (Batch No.: F3) in the buccal position of
oral cavity after light anesthetization of animals by an i.m
injection of 1:5 mixtures of xylazine (1.5 mg/kg) and ketamine
(9.0 mg/kg). Following the induction of anesthesia, blood sam-
ples (1.0 mL) were withdrawn from marginal ear vein of rab-
bits. Samples were withdrawn before dosing and 0.25, 0.5,
1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 12.0, 18.0, 24.0 h post dos-
ing. The light plane of anesthesia was maintained by an intra-
muscular (i.m) injection of one third of initial dose of xylazine
and ketamine as needed. Blood samples were collected in
1.5 mL centrifuge tubes containing 100 lL of EDTA solution
(1.0 mg/mL) and centrifuged at 4000 rpm for 4 min at 4 C
(Eppendorf centrifuge-5702R). The supernatant obtained was
collected and stored at 20 C till further processing for
analysis.
2.4.11. In-vivo plasma sample processing and estimation of drug
content
Stored plasma samples were thawed at ambient temperature
(25 ± 2 C) for at least 60 min. Before loading the sample in
SPE cartridge, cartridge was conditioned (1 mL methanol,
2500 rpm) and equilibrated (25 mM potassium dihydrogen
orthophosphate, 2500 rpm). Sample was loaded into cartridge
and centrifuged at 2000 rpm to remove interfering components
and matrix, washing step was performed using 3% v/v metha-
nol (1 mL, 2500 rpm) to remove the remaining interfering com-
ponents and ﬁnally elution was carried out using 0.025 M
phosphate buffer pH 3.0 and acetonitrile (75:25, 1 mL,
3000 rpm) solvent system. The separation was performed using
a centrifuge (Remi, India) and the elutions were collected in
5 mL disposable tubes.
The processed plasma samples were estimated for drug con-
tent using liquid chromatographic method mentioned earlier.
The plasma concentration vs. time data of BS obtained duringFigure 1 DSC thermogram obtained for pure drug BS (A), mannito
HPMC 15K in 1:1 ratio (E), MCC (F) and BS with MCC in 1:1 ratiovarious sets of studies was subjected to non-compartmental
analysis using WinNonlin Standard edition, Version 2.1
(WinNonlin Scientiﬁc Consultants, USA) to obtain various
pharmacokinetic parameters. Absolute bioavailability of
designed formulations was calculated using Eq. (2).
F ¼ ðDosei:vÞ  ðAUC01buccalÞðDosebuccalÞ  ðAUC01i:vÞ
ð2Þ3. Results and discussion
3.1. Drug excipient compatibility
DSC thermogram of pure drug showed two endothermic
(189.89 C and 204.43 C) and one exothermic (192.18 C)
peaks (Fig. 1). These values were close to values reported in
the literature (Sheikhzadeh et al., 2007). The endothermic peak
at 189.89 C was due to melting of pure drug sample. The exo-
thermic peak at 192.18 C was due to conversion of polymor-
phic form-1 of the drug to polymorphic form-2. The last
endothermic peak at 204.43 C was due to melting of recrystal-
lized form-2 of the drug. In the physical mixtures of BS with
HPMC and BS with cellulose microcrystalline (1:1), all the
three peaks were well retained (Fig. 1) indicating compatibility.
In DSC thermogram of pure mannitol, a sharp endother-
mic peak was observed at 168.4 C very near to that of the
drug. In physical mixture of drug and mannitol, a single, wide
endothermic peak was observed which can be attributed to
both BS and mannitol (Fig. 1). Thus, DSC being a thermal
method of analysis should not be used singly to detect any
inherent incompatibility. It has to be supported sufﬁciently
by other non-thermal techniques such as FTIR or chromato-
graphic techniques. To further understand the compatibility
of BS with process excipients, FTIR studies were performed.
FTIR spectroscopic analysis of pure drug revealed peaks spe-
ciﬁc to functional groups of BS. IR bands were obtained at
2949 cm1 for aromatic CAH stretching of pyrimidine,l (B), BS and mannitol in 1:1 ratio (C), HPMC 15K (D), BS and
(G).
Figure 2 FTIR spectrum obtained for pure drug, pure mannitol and physical mixture of BS-mannitol.
320 A. Jaipal et al.1724 cm1 for C‚O stretching. Moreover, bands were also
obtained at 1454 cm1 for CH2 bending of piperazine,
1338 cm1and 1165 cm1 for C‚C bending and 980 cm1
and 802 cm1 for aromatic CAH bending. All the characteris-
tic peaks of BS were retained in 1:1 physical mixtures of BSwith mannitol (Fig. 2) and other excipients used, indicating
compatibility. HPLC analysis of BS in the presence of manni-
tol did not alter peak characteristics and no degradation peaks
were observed; peak area was also well retained with respect to
analysis of pure BS. Thus, FTIR and HPLC studies together
Table 3 Coded factors, percent drug released at end of 5 h
(Q5), time required to release 50% of drug (T50) and
bioadhesive strength in Newton (FN) of the designed buccal
discs.
B. no Coded factors
X1 X2 Q5 (%) T50 (h) FN (N)
F1 1 1 82.69 1.58 9.57
F2 1 0 86.31 1.53 9.47
F3 1 +1 99.59 1.39 9.61
F4 0 1 79.02 1.76 10.39
F5 0 0 82.30 1.59 10.13
F6 0 +1 93.40 1.25 9.89
F7 +1 1 69.95 2.62 12.00
F8 +1 0 73.20 2.29 12.14
F9 +1 +1 79.15 2.18 11.97
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tol selected for this study. Overall, the results obtained from
DSC and FTIR studies conﬁrmed that BS is stable with the
process excipients used for the study.
3.2. Physical characteristics of designed buccal discs
Designed buccal discs demonstrated good physical characteris-
tics indicating suitability of the method and excipients used for
preparation. All the batches of buccal discs demonstrated per-
missible limit of percent error for weight variation (0.3–0.7%).
Thickness measurements (ranging between 2.39 and 2.51 mm
for all batches) indicated suitability of discs for buccal applica-
tion (Table 1). Friability of all the batches was within limits
(less than 1%) and surface pH was around 7.0 (Table 1). Assay
values of designed formulations were found to be acceptable
with a range of 98–102% (Table 1).
3.3. In-vitro water uptake studies
In in vitro water uptake studies, percent water uptake of
designed buccal discs increased with increasing proportion of
HPMC (Fig. 3). Increase in mannitol proportion also contrib-
uted to increased rate of water uptake (Fig. 3). This increased
hydration behavior with increasing proportion of mannitol rel-
ative to HPMC can be attributed to faster permeability of
aqueous medium into the matrix due to the formation of pores
or channels caused due to higher solubility of mannitol.
3.3.1. In vitro bioadhesion studies
In-vitro bioadhesion studies for the designed buccal discs were
investigated on porcine buccal mucosa using texture analyzer.
Bioadhesion is the force of attachment of material or dosage
form to the mucous secreting biological tissue or mucous mem-
brane. The force required to detach designed discs form the
mucosal membrane was determined using texture analyzerFigure 3 Water uptake behav(Jaipal et al., 2013). HPMC is a hydrophilic polymer with
many polar functional groups. Upon hydration the polymeric
chains of HPMC get entangled with glycoprotein chains of
mucin resulting in bioadhesion (Andrews et al., 2009; Jaipal
et al., 2013). The degree of bioadhesion depends on type and
amount of polymer, excipients used in the dosage form, degree
of hydration, polymer chain length and molecular weight of
polymer (Andrews et al., 2009; Charde et al., 2008; Salamat-
Miller et al., 2005). Designed HPMC buccal discs (F1–F9)
containing various proportions of HPMC and mannitol
demonstrated good in vitro bioadhesion. Increase in polymer
concentration resulted in increased force of adhesion (Table 3).
When the concentration of polymer is low, the number of
chains penetrating glycoprotein chains per unit volume of
mucous is low resulting in weaker interaction (Leung and
Robinson, 1990; Salamat-Miller et al., 2005; Smart, 2005).
Various theories have been proposed for bioadhesive behavior
of the polymers such as electronic interaction, hydrogen
bonding, electronic theory, adsorption theory, wettabilityior of buccal discs (n= 3).
Figure 4 Predicted vs. actual and surface response plots of drug release at 5 H (Q5 in%), 50% drug release (T50 in h) and bioadhesion
(FN in Newton) for the designed buccal discs.
322 A. Jaipal et al.theory and the diffusion and interlocking theory (Smart, 2005;
Sudhakar et al., 2006). Diffusion was the best suitable for
bioadhesive behavior of HPMC buccal discs, due to its
hydrophilic swellable characteristics (Heng et al., 2001). The
equation obtained for bioadhesive force (FN) using full facto-
rial design is as follows (Eq. (4))FN¼ 10:14þ1:24X10:08X20:02X1X2þ0:66X210:01X22
ð4Þ
The quadratic model was found to be signiﬁcant with F
value 55.24 (p< 0.0037). The relatively higher value
(P0.9713) of regression coefﬁcient for bioadhesive strength
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values compared to that of predicted values. Bioadhesive force
for the designed buccal discs increased signiﬁcantly with
increase in HPMC proportion (Fig. 4). High level of X1 gave
increased bioadhesive force at all levels of X2 factor, this indi-
cates factor X1 (HPMC) has signiﬁcant effect on bioadhesive
strength (Table 3). The results were according to previous the-
ories suggested in the literature (Leung and Robinson, 1990;
Peppas and Sahlin, 1996; Smart, 2005).3.3.2. In-vitro drug release studies: effect of formulation
variables
The in vitro release proﬁle of all the designed buccal discs is
given in Fig. 5. The model terms of Q5 (drug release at 5 h)
were found to be signiﬁcant with the F value 83.67
(p< 0.0020), with actual values close to the predicted values
(Eq. (5)). Regression coefﬁcient value (0.9810) nearer to one
indicated goodness of ﬁt (all factors were found to be
signiﬁcant).Figure 5 Drug release proﬁle of
Table 4 Model ﬁtting of in vitro drug release study for determinat
B. no Zero order First order
(R2) (R2)
F* = ko · t Mt=M0 ek1t
F1 0.6846 0.9775
F2 0.7154 0.9883
F3 0.7235 0.9956
F4 0.7587 0.9920
F5 0.7455 0.9944
F6 0.7326 0.9951
F7 0.8381 0.9833
F8 0.7782 0.9740
F9 0.7610 0.9683
F*, amount of drug dissolved at time t, ko, k1, kH, kp drug release rate c
model respectively.
‘‘n’’ is dissolution exponent of Korsmeyer–Peppas model.Q5 ¼ 82:66 7:72X1 þ 6:75X2  1:93X1X2  3:09X21 þ 3:36X22
ð5Þ
The model terms for T50% were also found to be signiﬁ-
cant with F value 38.90 (p< 0.0063), with actual values close
to predicted values (Fig. 4), with regression coefﬁcient value of
0.9595 (Eq. (6)).
T50 ¼ 1:54þ 0:43X1  0:19X2  0:06X1X2 þ 0:40X21  0:01X22
ð6Þ
Changes in factor X1 (HPMC) and factor X2 (mannitol)
inﬂuenced the drug release rate. The drug release rate
decreased with increasing proportion of HPMC in disc matrix
(Fig. 5). An increase in polymer proportion increases the
viscosity of gel layer and also results in gel layer with longer
diffusional path length resulting in greater retardation of drug
release (Table 3; Fig 5). Increase in proportion of mannitol
resulted in faster dissolution of drug and faster drug release
rate. This can be ascribed to formation of pore in disc matrix
due to higher and faster solubility of mannitol. This results indesigned buccal discs (n= 3).
ion of mechanism and kinetics of drug release.
Higuchi Korsmeyer–Peppas
(R2) (R2) n-value
ML,t = kH
p
t F= kp · tn
0.9535 0.9558 0.463
0.9577 0.9583 0.481
0.9713 0.9721 0.477
0.9814 0.9815 0.493
0.9780 0.9783 0.486
0.9745 0.9751 0.481
0.9907 0.9933 0.544
0.9872 0.9872 0.502
0.9858 0.9860 0.491
onstants of zero order, ﬁrst order, Higuchi’s and Korsmeyer–Peppas
Figure 6 Mean plasma concentration time proﬁle of BS following intravenous and buccal (F3) administration (n= 3).
Table 5 Pharmacokinetic parameters of BS when administered intravenously and via buccal route.
Pharmacokinetic parameters 10 mg BS solution (i.v) 10 mg buccal disc (F3)
AUC01 (ng h/mL)
a 5153.90 ± 430.81 2129.57 ± 623.19
F – 0.41 ± 0.09
Cmax (ng/mL)
a 1384.68 ± 467.21 262.32 ± 43.29
tmax (h) – 2.50
T1/2
a (h) 2.53 ± 0.12 5.94 ± 0.37
a Values are mean ± SD. n= 3.
324 A. Jaipal et al.the formation of channel through which the media can enter
the swollen polymer matrix and dissolve the drug. Information
expressed by 3-dimensional surface plots matches closely with
experimental results (Fig. 4). Low T50 values were observed
for the batches having higher level of factor X2 (mannitol)
due to pore formation. This effect was prominent at all levels
of factor X1 indicating rapid drug release due to increased
porosity of hydrogel matrix (Table 3).
Drug release observed from the designed HPMC matrices
(F1–F9) followed ﬁrst order release kinetics with n-values
ranging from 0.463 to 0.544 (Table 4), indicating the drug
release was non-Fickian anomalous type with polymer relaxa-
tion, diffusion and erosion being predominant mechanisms of
drug release.
3.3.3. In-vivo pharmacokinetic study
In-vivo pharmacokinetic study was carried out for BS
administered intravenously and for designed HPMC buccal
discs (F3). The drug was detectable within 15 min of buccal
administration indicating rapid absorption of released drug
(Fig. 6). After buccal administration the maximum concen-
tration was achieved within 2.5 h. In-vivo pharmacokinetic
parameters obtained during the study are tabulated in
Table 5. Absolute bioavailability of designed buccal discs
was 0.41. This value is considerably higher than oral bio-
availability of around 4% reported in the literature
(Mahmood and Sahajwalla, 1999). Hence, this demonstrates
usefulness of buccal delivery systems of BS for increase in
bioavailability.4. Conclusion
Effect of mannitol and HPMC on drug release and bioadhe-
sive behavior from the designed buccal discs was studied suc-
cessfully using a 32 factorial design. It can be concluded that
the drug release pattern can be changed by selection of appro-
priate levels of two factors viz HPMC and mannitol. Increase
in mannitol proportion resulted in faster drug release rate and
drug release rate decreased with increasing proportion of
HPMC in buccal disc. Bioadhesive strength of designed discs
increased with increasing proportion of HPMC in buccal discs.
Designed HPMC buccal discs were successfully evaluated for
pharmacokinetics parameters in rabbits and have demon-
strated considerable absolute bioavailability. From the above
study it can be concluded that HPMC bioadhesive buccal discs
can serve as a promising option for delivery of BS and the drug
release rate from the HPMC matrices can be adjusted by add-
ing water soluble mannitol as release modiﬁer.
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